

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015, India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

BSE Limited 1 st Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u>	National Stock Exchange of India Limited Exchange Plaza, 5 th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u>
Kind Attn.: Mr. Sanjay Golecha / Mr. Gopalkrishnan	Kind Attn.: Famroze Pochara Asst. Vice President
Date: June 13, 2017	
Re.: Press Release	

Dear Sir / Madam,

We enclose herewith a copy of press release dated June 13, 2017 titled "Zydus receives final approval from the USFDA for Ezetimibe Tablets USP; the drug is used to reduce high cholesterol levels".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking You,

Yours faithfully,
For, CADILA HEALTHCARE LIMITED


UPEN H. SHAH
COMPANY SECRETARY



Zydus receives final approval from the USFDA for Ezetimibe Tablets USP

The drug is used to reduce high cholesterol levels

Ahmedabad, 13 June 2017

Zydus Cadila has received the final approval from the USFDA to market Ezetimibe Tablets USP, 10 mg. Ezetimibe is a drug used to reduce high cholesterol levels. It will be produced at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

The estimated sales for Ezetimibe Tablets is \$2.7 billion as per IMS MAT April 2017.

The group now has more than 115 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
